These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28715286)

  • 1. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease.
    Rødgaard-Hansen S; St George A; Kazankov K; Bauman A; George J; Grønbæk H; Jon Møller H
    Scand J Clin Lab Invest; 2017 Nov; 77(7):498-504. PubMed ID: 28715286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children.
    Kazankov K; Møller HJ; Lange A; Birkebaek NH; Holland-Fischer P; Solvig J; Hørlyck A; Kristensen K; Rittig S; Handberg A; Vilstrup H; Grønbaek H
    Pediatr Obes; 2015 Jun; 10(3):226-33. PubMed ID: 25073966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
    Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
    Kazankov K; Barrera F; Møller HJ; Rosso C; Bugianesi E; David E; Younes R; Esmaili S; Eslam M; McLeod D; Bibby BM; Vilstrup H; George J; Grønbaek H
    Liver Int; 2016 Oct; 36(10):1549-57. PubMed ID: 27102725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
    Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
    J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.
    Kazankov K; Barrera F; Møller HJ; Bibby BM; Vilstrup H; George J; Grønbaek H
    Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
    Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
    J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease.
    Kazankov K; Alisi A; Møller HJ; De Vito R; Rittig S; Mahler B; Nobili V; Grønbæk H
    J Pediatr Gastroenterol Nutr; 2018 Nov; 67(5):635-642. PubMed ID: 30074574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
    Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
    Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The macrophage-specific serum marker, soluble CD163, is increased in obesity and reduced after dietary-induced weight loss.
    Fjeldborg K; Christiansen T; Bennetzen M; J Møller H; Pedersen SB; Richelsen B
    Obesity (Silver Spring); 2013 Dec; 21(12):2437-43. PubMed ID: 23512476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and β-cell Function.
    Semnani-Azad Z; Connelly PW; Johnston LW; Retnakaran R; Harris SB; Zinman B; Hanley AJ
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e285-94. PubMed ID: 31677389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.
    Lidofsky A; Holmes JA; Feeney ER; Kruger AJ; Salloum S; Zheng H; Seguin IS; Altinbas A; Masia R; Corey KE; Gustafson JL; Schaefer EA; Hunt PW; Deeks S; Somsouk M; Chew KW; Chung RT; Alatrakchi N
    J Infect Dis; 2018 Sep; 218(9):1394-1403. PubMed ID: 29868909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.
    Axelsson J; Møller HJ; Witasp A; Qureshi AR; Carrero JJ; Heimbürger O; Bárány P; Alvestrand A; Lindholm B; Moestrup SK; Stenvinkel P
    Am J Kidney Dis; 2006 Dec; 48(6):916-25. PubMed ID: 17162146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.
    Greisen SR; Møller HJ; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hvid M; Deleuran B
    Clin Exp Rheumatol; 2015; 33(4):498-502. PubMed ID: 25962601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals.
    Knudsen TB; Ertner G; Petersen J; Møller HJ; Moestrup SK; Eugen-Olsen J; Kronborg G; Benfield T
    J Infect Dis; 2016 Oct; 214(8):1198-204. PubMed ID: 27354366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis.
    Bossen L; Vesterhus M; Hov JR; Färkkilä M; Rosenberg WM; Møller HJ; Boberg KM; Karlsen TH; Grønbæk H
    Clin Transl Gastroenterol; 2021 Mar; 12(3):e00315. PubMed ID: 33646203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble CD163: a biomarker linking macrophages and insulin resistance.
    Parkner T; Sørensen LP; Nielsen AR; Fischer CP; Bibby BM; Nielsen S; Pedersen BK; Møller HJ
    Diabetologia; 2012 Jun; 55(6):1856-62. PubMed ID: 22450890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study.
    Björklund J; Laursen TL; Sandahl TD; Møller HJ; Vilstrup H; Ott P; Grønbæk H
    Orphanet J Rare Dis; 2018 Sep; 13(1):169. PubMed ID: 30241550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble CD163-Associated Dietary Patterns and the Risk of Metabolic Syndrome.
    Hu TY; Lee SY; Shih CK; Chou MJ; Wu MC; Teng IC; Bai CH; Sabrina N; Tinkov AA; Skalny AV; Chang JS
    Nutrients; 2019 Apr; 11(4):. PubMed ID: 31027316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular vesicle-associated soluble CD163 and CD206 in patients with acute and chronic inflammatory liver disease.
    Nielsen MC; Andersen MN; Grønbæk H; Damgaard Sandahl T; Møller HJ
    Scand J Gastroenterol; 2020 May; 55(5):588-596. PubMed ID: 32393080
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.